Speaker
Senior Manager - Biomarker Development, Immunic Therapeutics
Amelie Schreieck, Senior Manager - Biomarker Development at Immunic Therapeutics, is speaking at Novel CNS Biomarkers Summit Europe (London, United Kingdom, 30 Nov – 2 Dec 2026) in the session “Building the Translational Evidence for Nurr1 Activation in Multiple Sclerosis from Preclinical Discovery to Clinical Biomarkers”.
30 Nov – 2 Dec 2026London, United Kingdom
President & Chief Executive Officer, Progenra Inc
Vice President - Translational Biology, NRG Therapeutics
Neurological Disorders & Biofluid Specialist, Lundbeck
Founder & Chief Executive Officer, AltPep
Co-Founder & Chief Scientific Officer, Monument Therapeutics
Senior Scientist, Biosample Project Leader, Roche
This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Amelie Schreieck, and it lists only the talks, sessions and presentations named in those programmes.
Is this you? Claim this profile — every request is read by a person before anything is linked.
To ask for a correction or for this profile to be removed, email [email protected].